374 Shares in IDEXX Laboratories, Inc. $IDXX Acquired by Simplicity Wealth LLC

Simplicity Wealth LLC acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 374 shares of the company’s stock, valued at approximately $201,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Red Spruce Capital LLC boosted its stake in shares of IDEXX Laboratories by 1.1% in the 2nd quarter. Red Spruce Capital LLC now owns 1,701 shares of the company’s stock valued at $912,000 after buying an additional 19 shares during the period. Rise Advisors LLC boosted its stake in shares of IDEXX Laboratories by 3.9% in the 2nd quarter. Rise Advisors LLC now owns 562 shares of the company’s stock valued at $301,000 after buying an additional 21 shares during the period. Sage Mountain Advisors LLC boosted its stake in shares of IDEXX Laboratories by 3.8% in the 1st quarter. Sage Mountain Advisors LLC now owns 635 shares of the company’s stock valued at $267,000 after buying an additional 23 shares during the period. Great Lakes Advisors LLC boosted its stake in shares of IDEXX Laboratories by 0.9% in the 1st quarter. Great Lakes Advisors LLC now owns 2,567 shares of the company’s stock valued at $1,078,000 after buying an additional 23 shares during the period. Finally, PDS Planning Inc boosted its stake in shares of IDEXX Laboratories by 3.9% in the 1st quarter. PDS Planning Inc now owns 641 shares of the company’s stock valued at $269,000 after buying an additional 24 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on IDXX shares. UBS Group started coverage on IDEXX Laboratories in a research note on Wednesday, October 1st. They issued a “neutral” rating and a $720.00 price objective for the company. Jefferies Financial Group began coverage on IDEXX Laboratories in a research note on Tuesday, July 1st. They set a “buy” rating and a $625.00 target price for the company. Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research note on Sunday, September 28th. Piper Sandler restated a “neutral” rating and set a $700.00 target price (up previously from $510.00) on shares of IDEXX Laboratories in a research note on Monday, August 11th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of IDEXX Laboratories in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $656.50.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $629.91 on Thursday. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $688.12. The stock has a 50 day moving average of $637.99 and a two-hundred day moving average of $539.07. The stock has a market cap of $50.40 billion, a P/E ratio of 52.45, a P/E/G ratio of 4.06 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, beating analysts’ consensus estimates of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The company had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter in the previous year, the business earned $2.44 earnings per share. The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP Michael G. Erickson sold 406 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $649.96, for a total value of $263,883.76. Following the completion of the sale, the executive vice president owned 11,287 shares in the company, valued at approximately $7,336,098.52. The trade was a 3.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael Lane sold 8,411 shares of the business’s stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $627.74, for a total value of $5,279,921.14. Following the completion of the transaction, the executive vice president directly owned 7,132 shares in the company, valued at approximately $4,477,041.68. The trade was a 54.11% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 54,057 shares of company stock valued at $34,293,468 in the last 90 days. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.